Praed Pharma
- Biotech or pharma, therapeutic R&D
Praed Pharmaceuticals was founded by industry experts, formerly with Actelion (acquired by JnJ for $30B). Our mission is to deliver a next-gen treatment for Crohn’s disease with a lead program that is Ph2-ready.
Current treatments target the symptoms and disease progression but patients still progress relentlessly. Today, patients receive therapy with biologicals sooner or later.
Praed’s patent-protected oral agent aims to be effective in the treatment of Crohn’s through targeting MAP (Mycobacterium avium subspecies paratuberculosis), which is thought to be a cause of this disease. Our compound is highly active against MAP.
Due to a concluded Ph3 global clinical program in another GI indication, the compound’s safety profile and CMC are well established and accordingly, it is well suited for the chronic treatment of Crohn's on top of standard of care.
Praed is seeking a development partner to conduct a Ph2 trial in Crohn’s and commercialize the drug on a regional or worldwide basis.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}